Adagene Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- ADAGAdagene Inc10Calm
ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors
FinishedPhase 1/258 patientsMain results: Jan 29, 2024 - ADAGAdagene Inc0Calm
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
Signing up patientsPhase 1/2186 patientsMain results: Jun 30, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 5 purchases
- Tam Man KinChief Financial Officer · Sep 23, 2026Bought 2,000 sharesabout $6 thousand ·
- Luo PeterChief Executive Officer · Sep 16, 2026Bought 20,290 sharesabout $64 thousand ·
- DO CUONG VBoard member · Aug 14, 2026Bought 2,000 sharesabout $8 thousand ·
- Luo PeterChief Executive Officer · Aug 5, 2026Bought 279 sharesabout $1 thousand ·
- Luo PeterChief Executive Officer · Aug 4, 2026Bought 22,966 sharesabout $84 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.